<DOC>
	<DOCNO>NCT02172495</DOCNO>
	<brief_summary>Post-marketing surveillance gather information regard tolerance efficacy Spiriva® 18 microgram patient COPD condition daily practice .</brief_summary>
	<brief_title>Spiriva® Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Daily Practice</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Men woman age least 40 year symptoms Chronic Obstructive Pulmonary Disease Patients general specific contraindication list Patient Information Leaflet Basic Product Information</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>